MORF-057 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Diseases
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Trial Timeline
Nov 21, 2022 → Aug 1, 2026
NCT ID
NCT05611671About MORF-057 + Placebo
MORF-057 + Placebo is a phase 2 stage product being developed by Eli Lilly for Inflammatory Bowel Diseases. The current trial status is active. This product is registered under clinical trial identifier NCT05611671. Target conditions include Inflammatory Bowel Diseases, Colitis, Ulcerative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05611671 | Phase 2 | Active |
Competing Products
20 competing products in Inflammatory Bowel Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| CT-P13 | Celltrion | Phase 3 | 77 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 23 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| fidaxomicin | Astellas Pharma | Approved | 85 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Risankizumab | AbbVie | Approved | 85 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |